Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print Created with Sketch. YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Please Log In/Join Now first, and then use this function!

Recruiting

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread - CA030-001

Updated: 8 April, 2021   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 40

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Part 1A: BMS-986249
Biological: BMS-986249
Experimental: Part 1B: BMS-986249 + nivolumab (nivo)
Biological: Nivolumab Biological: BMS-986249
Experimental: Part 2A Arm A: BMS-986249 + nivo then nivo
Biological: BMS-986249 Biological: Nivolumab
Experimental: Part 2A Arm B: BMS-986249 + nivo
Biological: BMS-986249 Biological: Nivolumab
Experimental: Part 2A Arm C: BMS-986249 + nivo
Biological: Nivolumab Biological: BMS-986249
Experimental: Part 2A Arm D: ipilimumab + nivo then nivo
Biological: Nivolumab Biological: Ipilimumab
Experimental: Part 2A Arm E: Nivo
Biological: Nivolumab
Experimental: Part 2A Arm F: BMS-986249 + nivo
Biological: Nivolumab Biological: BMS-986249
Experimental: Part 2B Cohort 1: BMS-986249 + nivo
Biological: BMS-986249 Biological: Nivolumab
Experimental: Part 2B Cohort 2: BMS-986249 + nivo
Biological: BMS-986249 Biological: Nivolumab
Experimental: Part 2B Cohort 3: BMS-986249 + nivo
Biological: BMS-986249 Biological: Nivolumab

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Some participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies - Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants - Understand and sign an IRB/IEC-approved ICF prior to any study-specific evaluation - Willing and able to comply with all study procedures Exclusion Criteria: - Primary CNS malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded - Other active malignancy requiring concurrent intervention - Prior organ allograft - Active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us